Eli Casdin
CIK 1534264 · Officer (CEO) · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
WGSWW price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1140
NEW YORK, NY 10019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WGS | Director | 357,237 | $61.98 | $22.14M | $0 | 1 | 2026-06-23 |
| LAB | Director | 5,797,388 | $0.61 | $3.56M | $34.27M | 14 | 2026-06-23 |
| GeneDx Holdings Corp. (WGSWW) Delisted | Director | 3,027,682 | $0.00 | $606 | -$194.68M | 10 | 2025-08-22 |
| BLFS | 10%+ Owner | 16,306,694 | $38.61 | $629.60M | $26.38M | 4 | 2025-04-09 |
| 2seventy bio, Inc. (TSVT) Delisted | Director | 2,022,625 | $5.00 | $10.11M | $15.60M | 2 | 2024-06-12 |
| SomaLogic, Inc. (SLGCW) Delisted | Director | 10,138,865 | $0.09 | $871.9K | $0 | 5 | 2023-03-22 |
| EQRx, Inc. (EQRXW) Delisted | Director | 5,488,164 | $0.05 | $249.7K | $0 | 4 | 2023-01-04 |
| MXCT | 10%+ Owner | 10,000,000 | $1.58 | $15.85M | $75.50M | 2 | 2022-10-05 |
| TNYA | Director | 3,224,849 | $0.40 | $1.30M | $12.75M | 2 | 2022-06-13 |
| ABSI | Director | 973,260 | $10.01 | $9.74M | $25.00M | 2 | 2022-06-10 |
| IPSC | Director | 3,206,380 | $1.42 | $4.55M | $15.00M | 3 | 2022-06-10 |
| GeneDx Holdings Corp. (SMFRW) Delisted | Director | 16,450,336 | $0.02 | $394.8K | $45.75M | 6 | 2022-05-12 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 9,045 | $104.91 | $948.9K | $0 | 5 | 2020-07-24 |
| Generation Bio Co. (GBIO) Delisted | 10%+ Owner | 161,122 | $5.34 | $860.4K | $24.70M | 1 | 2020-06-18 |
| FULC | 10%+ Owner | 464,285 | $3.67 | $1.70M | $8.87M | 1 | 2019-07-22 |
Recent Filings · Page 5 of 7
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-04 | GeneDx Holdings Corp. (SMFRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-03 | GeneDx Holdings Corp. (SMFRW) Delisted | Buy (P) | +11,437,500 | $45.75M | EDGAR |
| 2022-04-06 | LAB | Grant (A) | +15,852 | $0 | EDGAR |
| 2022-03-03 | SomaLogic, Inc. (SLGCW) Delisted | Grant (A) | +3,430 | $0 | EDGAR |
| 2021-12-23 | EQRx, Inc. (EQRXW) Delisted | Mixed | +48,187,042 | $50.00M | EDGAR |
| 2021-12-21 | EQRx, Inc. (EQRXW) Delisted | Mixed | +48,187,043 | $50.00M | EDGAR |
| 2021-12-13 | SomaLogic, Inc. (SLGCW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-03 | BLFS | Other (J) | +504,740 | $0 | EDGAR |
| 2021-10-19 | GeneDx Holdings Corp. (SMFRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-09-03 | SomaLogic, Inc. (SLGCW) Delisted | Mixed | +19,189,082 | $25.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.